ELUVIA™
Drug-Eluting Vascular Stent System
Superior Results in the First Head-to-Head DES SFA Trial
Learn more about the IMPERIAL Clinical Trial
The Eluvia Drug-Eluting Stent System showed SUPERIOR results in the first head-to-head DES SFA Trial.
IMPERIAL Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against Cook Medical’s Zilver™ PTX™ Stent, single-blind, non-inferiority design; independent core lab adjudication.
Superiority determined in a post hoc analysis that was specified prior to unblinding. 12-Month Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value = 0.0144).
Product Overview
Advanced drug-eluting technology for peripheral artery disease.
Sustained Drug Release
Delivers paclitaxel when restenosis is most likely to occur.
Product Design
Built on the proven InnovaTM Stent platform.